Guy's & St Thomas Foundation Hospital
London, SE1 7EH, United Kingdom
NCT Number: NCT02470507
The immune response to kidney damage during acute kidney injury (AKI) is an important contributor to the prolonged lack of renal function and progression of kidney injury. Most data related to intrarenal and interorgan pathways in AKI stem from animal research with sometimes conflicting results. Accurate evaluation of these processes in humans and identification of early diagnostic tools are critical for the development of strategies to prevent and attenuate AKI-related morbidity and mortality in patients.
The aim of this study is to evaluate immune function and miRNA expression in hospitalised patients with and without AKI.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
London, SE1 7EH, United Kingdom
Hypothesis:
An overriding pro-inflammatory immune response underlies AKI in humans which contributes to dysfunction of non-renal organs
Principal research question:
Is AKI in humans associated with a predominantly pro-inflammatory immune response?
Secondary research questions:
Study design:
Observational non-interventional study
Study population:
30 patients with AKI stage II or III * and systemic inflammation without sepsis 30 patients with AKI stage II or III * and no systemic inflammation 30 patients with systemic inflammation and normal renal function 30 patients after major surgery who do not have an infection, SIRS or AKI
Primary outcome Detection of measurable phenotypic characteristics and function of leukocytes that are specific of patients with AKI.
Secondary outcomes:
Statistical analysis:
For the analysis of laboratory variables that describe the immunological phenotype, standard statistical methods will be applied. 1) When the normal distribution assumption is met, groups will be compared using ANOVA and the corresponding contrasts for group by group comparisons; 2) In the absence of normality or for ordinal variables, Kruskal Wallis will be applied for multi-group comparisons, and Wilcoxon for two-groups analysis. We will apply multiple testing correction via Benjamini-Hochberg FDR control.
For the analysis of miRNA array data, we will first follow the protocol quality control measures appropriate for the platform of choice, and subsequently will carry out statistical analysis using the SAMr and LIMMA packages from Bioconductor, via the R software. Similarly, for the analysis of PCR data, the package HTqPCR from bioconductor will be used for quality control. Depending on the distribution of the final data, either non-parametric statistics, or a moderated t-test will be applied for statistical comparisons, with the corresponding multiple testing corrections as above.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
development of immune dysregulation and rise in inflammatory markers and activation of immune cells
Time frame: 7 days
Time frame: 7 days
Time frame: 7 days
Time frame: 7 days
Time frame: 7 days
Time frame: 7 days
Correlation between microRNA levels in patients with AKI and patient outcome Differences in cytokine profiles between AKI patients without systemic inflammation and patients without AKI and without systemic inflammation / infection.
Time frame: 7 days
Differences in cytokine profiles between AKI patients without systemic inflammation and patients without AKI and without systemic inflammation / infection.
Time frame: 7 days
Guy's and St Thomas' NHS Foundation Trust
Other
Evaluation of Immune Function in Patients With Acute Kidney Injury
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07579390
Acute Kidney Failure, Acute Kidney Injury
Brisbane, Australia
View Trial DetailsNCT03655561
Acute Kidney Failure, Acute Kidney Injury
Abakaliki, Ebonyi State, Nigeria
View Trial DetailsNCT07645365
Acute Kidney Failure, Acute Kidney Injury
Antalya, konyaaltı, Turkey (Türkiye)
View Trial DetailsNCT07132619
Acute Kidney Failure, Acute Kidney Injury
Istanbul, Kartal, Turkey (Türkiye)
View Trial Details